Last reviewed · How we verify
Rivaroxaban Oral Tablet
Rivaroxaban is a direct Factor Xa inhibitor that blocks the coagulation cascade to prevent blood clot formation.
Rivaroxaban is a direct Factor Xa inhibitor that blocks the coagulation cascade to prevent blood clot formation. Used for Atrial fibrillation for stroke prevention, Deep vein thrombosis (DVT) treatment and prevention, Pulmonary embolism (PE) treatment and prevention.
At a glance
| Generic name | Rivaroxaban Oral Tablet |
|---|---|
| Sponsor | Swiss Paraplegic Research, Nottwil |
| Drug class | Direct Factor Xa inhibitor |
| Target | Factor Xa |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Rivaroxaban selectively inhibits Factor Xa, a key enzyme in the intrinsic and extrinsic coagulation pathways. By blocking Factor Xa, it prevents the conversion of prothrombin to thrombin, thereby reducing thrombin generation and inhibiting clot formation. This anticoagulant effect is used to prevent and treat thrombotic events.
Approved indications
- Atrial fibrillation for stroke prevention
- Deep vein thrombosis (DVT) treatment and prevention
- Pulmonary embolism (PE) treatment and prevention
- Acute coronary syndrome
- Thromboprophylaxis after hip or knee replacement surgery
Common side effects
- Bleeding
- Gastrointestinal bleeding
- Intracranial hemorrhage
- Dyspepsia
- Abdominal pain
Key clinical trials
- The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease (PHASE4)
- Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease (PHASE3)
- Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves (PHASE3)
- Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis (PHASE1)
- A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants (PHASE1)
- Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke (PHASE4)
- Long-term Anticoagulation With Oral Factor Xa Inhibitor Versus Vitamin K Antagonist After Mechanical Aortic Valve Replacement (PHASE4)
- Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rivaroxaban Oral Tablet CI brief — competitive landscape report
- Rivaroxaban Oral Tablet updates RSS · CI watch RSS
- Swiss Paraplegic Research, Nottwil portfolio CI